Stocks Health care SPRB
NASDAQ · Health careSpruce Biosciences, Inc. (SPRB)
It posted a net loss of $67.1M. At September 30, 2026 it held $87.7M in cash against $19.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Spruce Biosciences, Inc.
- Net worth
- Spruce Biosciences, Inc. has a market value (market cap) of $135.1M at the latest share price, and shareholders' equity of $66.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $39M.
- Cash flow
- In fiscal 2025 operations used $33.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Spruce Biosciences, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Spruce Biosciences, Inc. does
Spruce Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SPRB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$39M | -$50.83 | n/a |
| 2024 | $4.9M | -$53M | -$96.40 | -$56M |
| 2023 | $10.1M | -$47.9M | -$92.66 | -$33.3M |
| 2022 | $0 | -$46.2M | -$146.47 | -$41.7M |
| 2021 | n/a | -$42.3M | -$135.26 | -$36M |
| 2020 | n/a | -$29.5M | -$368.41 | -$27.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Spruce Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 12, 2026
- August 4, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Spruce Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Szwarcberg Javier B.CHIEF EXECUTIVE OFFICER, Director | Received as pay | 266 | $1.2K |
| December 31, 2025 | Szwarcberg Javier B.CHIEF EXECUTIVE OFFICER, Director | Received as pay | 4,690 | $21.2K |
| December 15, 2025 | Gharib Samir M.PRESIDENT AND CFO | Exercised options | 496 | - |
| December 15, 2025 | Gharib Samir M.PRESIDENT AND CFO | Shares withheld for tax | 178 | $14.4K |
| December 15, 2025 | Gharib Samir M.PRESIDENT AND CFO | Exercised options | 513 | - |
| December 15, 2025 | Gharib Samir M.PRESIDENT AND CFO | Shares withheld for tax | 184 | $14.8K |
| December 15, 2025 | Szwarcberg Javier B.CHIEF EXECUTIVE OFFICER, Director | Exercised options | 1,480 | - |
| December 15, 2025 | Szwarcberg Javier B.CHIEF EXECUTIVE OFFICER, Director | Shares withheld for tax | 752 | $60.7K |
Who owns SPRB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orin Hirschman13G, passive with 1 related filers | 9.1% | July 27, 2026 |
| Boone Peter David Mr13G, passive | 6.4% | November 24, 2025 |
| Integrated Core Strategies (US) LLC13G, passive with 3 related filers | 5.8% | August 4, 2026 |
| AWM Investment Company, Inc.13G, passive | 5.1% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 63 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| AIGH Capital Management LLC | 250,000 | new |
| Orbimed Advisors LLC | 200,000 | new |
| BlackRock, Inc. | 187,836 | +170,898 |
| Millennium Management LLC | 160,981 | +49,093 |
| Ikarian Capital, LLC | 121,356 | 0 |
| Vanguard Capital Management LLC | 119,331 | +100,994 |
| Alyeska Investment Group, L.P. | 81,671 | +30,000 |
| Geode Capital Management, LLC | 70,548 | +57,659 |
| ADAR1 Capital Management, LLC | 67,717 | +9,117 |
| Cable Car Capital, LP | 60,000 | new |
| Citadel Advisors LLC | 51,905 | -18,094 |
| State Street Corp | 50,450 | +45,050 |
| Boothbay Fund Management, LLC | 42,080 | 0 |
| Stempoint Capital LP | 41,388 | +28,668 |
| Eversept Partners, LP | 40,000 | new |
| Carlyle Group Inc. | 38,620 | 0 |
| Goldman Sachs Group Inc | 32,348 | +26,842 |
| Affinity Asset Advisors, LLC | 30,000 | new |
| Diadema Partners LP | 30,000 | +20,000 |
| Stonepine Capital Management, LLC | 28,795 | new |
Insiders
3 insiders reported holding 28,783 shares in total, about $1.4M at the last price.
| Holder | Shares |
|---|---|
| Szwarcberg Javier B.CHIEF EXECUTIVE OFFICER, Director | 19,270 |
| Gharib Samir M.PRESIDENT AND CFO | 8,263 |
| Ways Douglas KirkInterim Chief Medical Officer, Director | 1,250 |
Questions about SPRB
What does Spruce Biosciences, Inc. do?
Spruce Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as SPRB. Its shares trade on NASDAQ under the ticker SPRB.
What is Spruce Biosciences, Inc.'s net worth?
Spruce Biosciences, Inc. has a market value (market cap) of $135.1M at the latest share price, and shareholders' equity of $66.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Spruce Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $67.1M.
When did Spruce Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Spruce Biosciences, Inc.'s next earnings report?
Spruce Biosciences, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SPRB with
Follow SPRB
Get an email when Spruce Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Spruce Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.